Evidence map›Paper›PMID 30169018›Full record

ArticleACS sensors2018

A Fluorescent Carbon Nanotube Sensor Detects the Metastatic Prostate Cancer Biomarker uPA.

Ryan M Williams, Christopher Lee, Daniel A Heller

Open access · greenAbstract read
In one paragraph

Article in ACS sensors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 119 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. High-throughput SWCNT NIR-II screening enables cell andbioRxiv : the preprint server for biology · 2026
    Article
  11. Article
  12. Review
  13. Near-Infrared Fluorescent Single-Walled Carbon Nanotubes for Biosensing.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ryan M WilliamsMemorial Sloan Kettering Cancer Center , New York , New York 10065 , United States.ORCID 0000-0002-2381-8732
Christopher LeeMemorial Sloan Kettering Cancer Center , New York , New York 10065 , United States.
Daniel A HellerMemorial Sloan Kettering Cancer Center , New York , New York 10065 , United States.ORCID 0000-0002-6866-0000
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Transient Metabolite Detection for Single-Cell Metabolomics and DiagnosticsDP2HD075698 · NICHD · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN · 2012 to 2012
$2.7M
NCI NIH HHS P30 CA008748NICHD NIH HHS DP2 HD075698
6 · The paper itself

Abstract

Therapeutic outcomes in patients with prostate cancer are hindered by the inability to discern indolent versus aggressive disease. To address this problem, we developed a quantitative fluorescent nanosensor for the cancer biomarker urokinase plasminogen activator (uPA). We used the unique fluorescent characteristics of single-walled carbon nanotubes (SWCNT) to engineer an optical sensor that responds to uPA via optical bandgap modulation in complex protein environments. The sensing characteristics of this construct were modulated by passivation of the hydrophobic SWCNT surface with bovine serum albumin (BSA). The sensor enabled quantitative detection of known uPA concentrations in human blood products. These experiments potentiate future use of this technology as a rapid, point-of-care sensor for biomarker measurements in patient fluid samples. We expect that further work will develop a method to discern aggressive vs indolent prostate cancer and reduce overtreatment of this disease.

Indexed as

AnimalsBiomarkers, TumorCattleFluorescenceFluorescent DyesHumansLimit of DetectionMaleNanotubes, CarbonPoint-of-Care TestingProstatic NeoplasmsSerum Albumin, BovineSpectrometry, FluorescenceUrokinase-Type Plasminogen ActivatorBiomarkers, TumorFluorescent DyesNanotubes, CarbonSerum Albumin, BovineUrokinase-Type Plasminogen Activatorbiosensornanocarbonnanomedicineoptical sensorprostatic carcinomaprotein

Identifiers

PMID30169018
PMCPMC11929042
OpenAlexW2889322502

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.